摘要
目的:比较那格列奈联合二甲双胍与单用二甲双胍治疗初发型2型糖尿病的疗效,不良反应及对胰岛β细胞功能的影响。方法:将120例初发2型糖尿病患者随机分为那格列奈+二甲双胍组(68例)和二甲双胍组(52例)观察12周,比较二组治疗前、后血糖控制情况(糖化血红蛋白7次血糖)、胰岛素用量、低血糖发生率、空腹C肽、餐后2hC肽的变化。结果:那格列奈+二甲双胍和单用二甲双胍具有显著的降低血糖和改善胰岛β细胞分泌的作用,治疗前、后比较差异有统计学意义(P<0.01),那格列奈+二甲双胍的3餐后血糖得到明显改善,低血糖发生率增加一半,差异有统计学意义(P<0.01),两组患者未观察到明显不良反应。结论:那格列奈+二甲双胍能更好地控制餐后血糖,但比单用二甲双胍有增加餐后低血糖的风险。
Objective： To compare effects of single Metformin and combination of Metformin and Nateglinide on first diagnosed type2 diabetes. Methods： 120 cases of first diagnosed type2 diabetes were randomly divided into Mefformin group （52 cases） and Mefformin plus Nateglinide group （68 cases）. In each group, data of blood glucose, HbA1c, fasting C-peptide, incidence of hypoglycemia, and insuline application before and after the treatment were compared. ResUlts： In both groups, blood glucose level were obviously decreased, secretion function of beta cell of islet were significantly improved after the treatment （P 〈 0.01 ）. No obvious adverse reactions were observed. What＇s more, in Metformin plus Nateglinide group, the Postprandial Blood Glucose were specifically decreased, the incidence of hypoglycemia decreased by half （P 〈0.01 ）. Conclusion： Combination of Metformin and Nateglinide is more effective in controlling Postprandial Blood Glucose while has higher risk of inducing postprandial hypoglycemia than single Mefformin.
出处
《海南医学院学报》
CAS
2009年第3期274-275,共2页
Journal of Hainan Medical University
